Sökning: WFRF:(Hahnen Eric) > (2016) > Van Rensburg Elizabeth J. > Inheritance of dele...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 11074naa a2201585 4500 | |
001 | oai:lup.lub.lu.se:e9fbd2af-125e-425d-84cf-fbd3c4ea8799 | |
003 | SwePub | |
008 | 161229s2016 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/e9fbd2af-125e-425d-84cf-fbd3c4ea87992 URI |
024 | 7 | a https://doi.org/10.1186/s13058-016-0768-32 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Rebbeck, Timothy R.u Dana-Farber Cancer Institute4 aut |
245 | 1 0 | a Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women |
264 | c 2016-11-11 | |
264 | 1 | b Springer Science and Business Media LLC,c 2016 |
520 | a Background: Most BRCA1 or BRCA2 mutation carriers have inherited a single (heterozygous) mutation. Transheterozygotes (TH) who have inherited deleterious mutations in both BRCA1 and BRCA2 are rare, and the consequences of transheterozygosity are poorly understood. Methods: From 32,295 female BRCA1/2 mutation carriers, we identified 93 TH (0.3 %). "Cases" were defined as TH, and "controls" were single mutations at BRCA1 (SH1) or BRCA2 (SH2). Matched SH1 "controls" carried a BRCA1 mutation found in the TH "case". Matched SH2 "controls" carried a BRCA2 mutation found in the TH "case". After matching the TH carriers with SH1 or SH2, 91 TH were matched to 9316 SH1, and 89 TH were matched to 3370 SH2. Results: The majority of TH (45.2 %) involved the three common Jewish mutations. TH were more likely than SH1 and SH2 women to have been ever diagnosed with breast cancer (BC; p = 0.002). TH were more likely to be diagnosed with ovarian cancer (OC) than SH2 (p = 0.017), but not SH1. Age at BC diagnosis was the same in TH vs. SH1 (p = 0.231), but was on average 4.5 years younger in TH than in SH2 (p < 0.001). BC in TH was more likely to be estrogen receptor (ER) positive (p = 0.010) or progesterone receptor (PR) positive (p = 0.013) than in SH1, but less likely to be ER positive (p < 0.001) or PR positive (p = 0.012) than SH2. Among 15 tumors from TH patients, there was no clear pattern of loss of heterozygosity (LOH) for BRCA1 or BRCA2 in either BC or OC. Conclusions: Our observations suggest that clinical TH phenotypes resemble SH1. However, TH breast tumor marker characteristics are phenotypically intermediate to SH1 and SH2. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Medicinsk genetik0 (SwePub)301072 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Medical Genetics0 (SwePub)301072 hsv//eng |
653 | a BRCA1 | |
653 | a BRCA2 | |
653 | a Hereditary breast and ovarian cancer | |
653 | a Transheterozygosity | |
700 | 1 | a Friebel, Tara M.u Dana-Farber Cancer Institute4 aut |
700 | 1 | a Mitra, Nanditau University of Pennsylvania4 aut |
700 | 1 | a Wan, Feiu Kaiser Permanente Research Institute4 aut |
700 | 1 | a Chen, Stephanieu University of Southern California4 aut |
700 | 1 | a Andrulis, Irene L.u University of Toronto4 aut |
700 | 1 | a Apostolou, Paraskeviu National Centre for Scientific Research Demokritos4 aut |
700 | 1 | a Arnold, Norbertu University Medical Center Schleswig-Holstein4 aut |
700 | 1 | a Arun, Banu K.u University of Texas4 aut |
700 | 1 | a Barrowdale, Danielu QIMR Berghofer Medical Research Institute4 aut |
700 | 1 | a Benitez, Javieru Spanish National Cancer Research Center (CNIO)4 aut |
700 | 1 | a Berger, Raananu Sheba Medical Center4 aut |
700 | 1 | a Berthet, Pascalineu Centre François Baclesse4 aut |
700 | 1 | a Borg, Åkeu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Familjär bröstcancer,Forskargrupper vid Lunds universitet,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Familial Breast Cancer,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)onk-abo |
700 | 1 | a Buys, Saundra S.u Huntsman Cancer Institute4 aut |
700 | 1 | a Caldes, Trinidadu Hospital Clinico San Carlos de Madrid4 aut |
700 | 1 | a Carter, Jonathanu Royal Prince Alfred Hospital4 aut |
700 | 1 | a Chiquette, Jocelyneu Hôpital du Saint-Sacrement4 aut |
700 | 1 | a Claes, Kathleen B Mu Ghent University Hospital4 aut |
700 | 1 | a Couch, Fergus J.u Mayo Clinic Minnesota4 aut |
700 | 1 | a Cybulski, Cezaryu Pomeranian Medical University4 aut |
700 | 1 | a Daly, Mary B.u Fox Chase Cancer Center4 aut |
700 | 1 | a de la Hoya, Miguelu Hospital Clinico San Carlos de Madrid4 aut |
700 | 1 | a Diez, Orlandu Vall d'Hebron University Hospital4 aut |
700 | 1 | a Domchek, Susan M.u Cochin Hospital4 aut |
700 | 1 | a Nathanson, Katherine L.u Cochin Hospital4 aut |
700 | 1 | a Durda, Katarzynau Pomeranian Medical University4 aut |
700 | 1 | a Ellis, Steveu University of Cambridge4 aut |
700 | 1 | a Evans, D. Garethu Manchester University NHS Foundation Trust,University of Manchester4 aut |
700 | 1 | a Foretova, Lenkau Masaryk Memorial Cancer Institute4 aut |
700 | 1 | a Friedman, Eitanu Tel-Aviv University4 aut |
700 | 1 | a Frost, Debrau University of Cambridge4 aut |
700 | 1 | a Ganz, Patricia A.u Jonsson Comprehensive Cancer Center4 aut |
700 | 1 | a Garber, Judyu Dana-Farber Cancer Institute4 aut |
700 | 1 | a Glendon, Gordu Mount Sinai Hospital of University of Toronto4 aut |
700 | 1 | a Godwin, Andrew K.u University of Kansas Medical Center4 aut |
700 | 1 | a Greene, Mark H.u National Cancer Institute, USA4 aut |
700 | 1 | a Gronwald, Jaceku Pomeranian Medical University4 aut |
700 | 1 | a Hahnen, Ericu University Hospital of Cologne4 aut |
700 | 1 | a Hallberg, Emilyu Mayo Clinic Scottsdale-Phoenix, Arizona4 aut |
700 | 1 | a Hamann, Uteu German Cancer Research Centre4 aut |
700 | 1 | a Hansen, Thomas V Ou Copenhagen University Hospital4 aut |
700 | 1 | a Imyanitov, Evgeny N.u N. N. Petrov Institute of Oncology4 aut |
700 | 1 | a Isaacs, Claudineu Lombardi Comprehensive Cancer Center4 aut |
700 | 1 | a Jakubowska, Annau Pomeranian Medical University4 aut |
700 | 1 | a Janavicius, Ramunasu State Research Institute Centre for Innovative Medicine4 aut |
700 | 1 | a Jaworska-Bieniek, Katarzynau Pomeranian Medical University4 aut |
700 | 1 | a John, Esther M.u Cancer Prevention Institute of California4 aut |
700 | 1 | a Karlan, Beth Y.u Cedars-Sinai Medical Center4 aut |
700 | 1 | a Kaufman, Bellau Sheba Medical Center4 aut |
700 | 1 | a Kwong, Avau University of Hong Kong4 aut |
700 | 1 | a Laitman, Yaelu Tel-Aviv University4 aut |
700 | 1 | a Lasset, Christineu Centre Léon Bérard4 aut |
700 | 1 | a Lazaro, Conxiu Bellvitge Biomedical Research Institute4 aut |
700 | 1 | a Lester, Jennyu Cedars-Sinai Medical Center4 aut |
700 | 1 | a Loman, Niklasu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital4 aut0 (Swepub:lu)onk-nlo |
700 | 1 | a Lubinski, Janu Pomeranian Medical University4 aut |
700 | 1 | a Manoukian, Siranoushu Istituto Nazionale dei Tumori4 aut |
700 | 1 | a Mitchell, Gillianu University of Melbourne4 aut |
700 | 1 | a Montagna, Marcou Veneto Institute of Oncology4 aut |
700 | 1 | a Neuhausen, Susan L.u City of Hope National Medical Center4 aut |
700 | 1 | a Nevanlinna, Heliu University of Helsinki4 aut |
700 | 1 | a Niederacher, Dieteru University Hospital of Düsseldorf4 aut |
700 | 1 | a Nussbaum, Robert L.4 aut |
700 | 1 | a Offit, Kennethu Memorial Sloan-Kettering Cancer Center4 aut |
700 | 1 | a Olah, Edithu National Institute of Oncology, Budapest4 aut |
700 | 1 | a Olopade, Olufunmilayo I.4 aut |
700 | 1 | a Park, Sue Kyungu Seoul National University4 aut |
700 | 1 | a Piedmonte, Marionu Roswell Park Cancer Institute4 aut |
700 | 1 | a Radice, Paolou Istituto Nazionale dei Tumori4 aut |
700 | 1 | a Rappaport-Fuerhauser, Christineu Medical University of Vienna4 aut |
700 | 1 | a Rookus, Matti A.u Netherlands Cancer Institute4 aut |
700 | 1 | a Seynaeve, Carolineu Erasmus University Medical Center4 aut |
700 | 1 | a Simard, Jacquesu Laval University4 aut |
700 | 1 | a Singer, Christian F.u Medical University of Vienna4 aut |
700 | 1 | a Soucy, Pennyu Laval University4 aut |
700 | 1 | a Southey, Melissau University of Melbourne4 aut |
700 | 1 | a Stoppa-Lyonnet, Dominiqueu Curie Institute, Paris4 aut |
700 | 1 | a Sukiennicki, Grzegorzu Pomeranian Medical University4 aut |
700 | 1 | a Szabo, Csilla I.u National Human Genome Research Institute4 aut |
700 | 1 | a Tancredi, Mariellau University Hospital of Pisa4 aut |
700 | 1 | a Teixeira, Manuel R.u Instituto Português de Oncologia do Porto Francisco Gentil (IPO)4 aut |
700 | 1 | a Teo, Soo Hwangu University of Malaya4 aut |
700 | 1 | a Terry, Mary Bethu Columbia University4 aut |
700 | 1 | a Thomassen, Madsu Odense University Hospital4 aut |
700 | 1 | a Tihomirova, Laimau Latvian Biomedical Research and Study Centre4 aut |
700 | 1 | a Tischkowitz, Marcu McGill University4 aut |
700 | 1 | a Toland, Amanda Ewartu Ohio State University4 aut |
700 | 1 | a Toloczko-Grabarek, Aleksandrau Pomeranian Medical University4 aut |
700 | 1 | a Tung, Nadineu Beth Israel Deaconess Medical Center4 aut |
700 | 1 | a van Rensburg, Elizabeth J.u University of Pretoria4 aut |
700 | 1 | a Villano, Danylou Memorial Sloan-Kettering Cancer Center4 aut |
700 | 1 | a Wang-Gohrke, Shanu University Hospital of Ulm4 aut |
700 | 1 | a Wappenschmidt, Barbarau University Hospital of Cologne4 aut |
700 | 1 | a Weitzel, Jeffrey N.u City of Hope National Medical Center4 aut |
700 | 1 | a Zidan, Jamalu Bar-Ilan University4 aut |
700 | 1 | a Zorn, Kristin K.4 aut |
700 | 1 | a McGuffog, Lesleyu University of Cambridge4 aut |
700 | 1 | a Easton, Douglasu University of Cambridge4 aut |
700 | 1 | a Chenevix-Trench, Georgiau QIMR Berghofer Medical Research Institute4 aut |
700 | 1 | a Antoniou, Antonis C.u University of Cambridge4 aut |
700 | 1 | a Ramus, Susan J.u University of New South Wales4 aut |
710 | 2 | a Dana-Farber Cancer Instituteb University of Pennsylvania4 org |
773 | 0 | t Breast Cancer Researchd : Springer Science and Business Media LLCg 18:1q 18:1x 1465-5411x 1465-542X |
856 | 4 | u http://dx.doi.org/10.1186/s13058-016-0768-3x freey FULLTEXT |
856 | 4 | u https://doi.org/10.1186/s13058-016-0768-3 |
856 | 4 8 | u https://lup.lub.lu.se/record/e9fbd2af-125e-425d-84cf-fbd3c4ea8799 |
856 | 4 8 | u https://doi.org/10.1186/s13058-016-0768-3 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy